I agree that this site is using cookies. You can find further informations here.
X
Sandra Robrecht
94  results:
Search for persons X
?
1

Bendamustine, followed by ofatumumab and ibrutinib in chron..:

Paula Cramer ; Julia v. Tresckow ; Sandra Robrecht...
Haematologica.  106 (2020)  2 - p. 543-554 , 2020
Link: https://doi.org/10.3324/..
 
?
2

Prognostic impact of prevalent chronic lymphocytic leukemia..:

Sonia Jaramillo ; Andreas Agathangelidis ; Christof Schneider...
Haematologica.  105 (2019)  11 - p. 2598-2607 , 2019
Link: https://doi.org/10.3324/..
 
?
3

Bendamustine, followed by obinutuzumab and idelalisib in ch..:

Cramer, Paula ; von Tresckow, Julia ; Fink, Anna‐Maria...
American Journal of Hematology.  99 (2024)  6 - p. 1192-1195 , 2024
Link: https://doi.org/10.1002/..
 
?
4

Fludarabine, cyclophosphamide, and rituximab as first‐line ..:

Kutsch, Nadine ; Giza, Adam ; Robrecht, Sandra...
European Journal of Haematology.  113 (2024)  2 - p. 235-241 , 2024
Link: https://doi.org/10.1111/..
 
?
5

Hybrid immunity to SARS‐CoV‐2 in patients with chronic lymp..:

Mellinghoff, Sibylle C. ; Robrecht, Sandra ; Sprute, Rosanne...
European Journal of Haematology.  112 (2024)  5 - p. 788-793 , 2024
Link: https://doi.org/10.1111/..
 
?
6

Infections in patients with chronic lymphocytic leukemia tr..:

Langerbeins, Petra ; Giza, Adam ; Robrecht, Sandra...
American Journal of Hematology.  , 2024
Link: https://doi.org/10.1002/..
 
?
7

First-line venetoclax combinations versus chemoimmunotherap..:

Fürstenau, Moritz ; Kater, Arnon P ; Robrecht, Sandra...
The Lancet Oncology.  25 (2024)  6 - p. 744-759 , 2024
Link: https://doi.org/10.1016/..
 
?
8

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATI..:

Langerbeins, Petra ; Robrecht, Sandra ; Nieper, Pascal...
HemaSphere.  7 (2023)  S3 - p. e9488123 , 2023
Link: https://doi.org/10.1097/..
 
?
9

Author Correction: Transcriptomic profiles and 5-year resul..:

Al-Sawaf, Othman ; Zhang, Can ; Jin, Hyun Yong...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
10

Transcriptomic profiles and 5-year results from the randomi..:

Al-Sawaf, Othman ; Zhang, Can ; Jin, Hyun Yong...
Nature Communications.  14 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
11

The proto-oncogene TCL1A deregulates cell cycle and genomic..:

Stachelscheid, Johanna ; Jiang, Qu ; Aszyk, Christoph...
Blood.  141 (2023)  12 - p. 1425-1441 , 2023
Link: https://doi.org/10.1182/..
 
?
12

Oncogenic role and target properties of the lysine-specific..:

Jiang, Qu ; Stachelscheid, Johanna ; Bloehdorn, Johannes...
Blood.  , 2023
Link: https://doi.org/10.1182/..
 
?
13

Treatment with idelalisib in patients with chronic lymphocy..:

von Tresckow, Julia ; Heyl, Nikola ; Robrecht, Sandra...
Annals of Hematology.  102 (2023)  11 - p. 3083-3090 , 2023
Link: https://doi.org/10.1007/..
 
?
14

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRO..:

Al-Sawaf, Othman ; Robrecht, Sandra ; Zhang, Can...
HemaSphere.  7 (2023)  S3 - p. e064430a , 2023
Link: https://doi.org/10.1097/..
 
?
15

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBIN..:

Yosifov, Deyan ; von Tresckow, Julia ; Giza, Adam...
HemaSphere.  7 (2023)  S3 - p. e14818fb , 2023
Link: https://doi.org/10.1097/..
 
1-15